# Comparative Study of Sensitivity of Ga-DOTATOC PET vs Octreoscan SPECT + CT

> **NCT01869725** · PHASE2 · COMPLETED · sponsor: **Sue O'Dorisio** · enrollment: 68 (actual)

## Conditions studied

- Adult Medulloblastoma
- Childhood Medulloblastoma
- Neuroblastoma
- Neuroendocrine Tumor
- Somatostatinoma

## Interventions

- **DRUG:** gallium Ga 68-edotreotide
- **PROCEDURE:** positron emission tomography/computed tomography
- **RADIATION:** indium In 111 pentetreotide
- **PROCEDURE:** computed tomography
- **PROCEDURE:** contrast-enhanced magnetic resonance imaging

## Key facts

- **NCT ID:** NCT01869725
- **Lead sponsor:** Sue O'Dorisio
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2013-04-01
- **Primary completion:** 2018-12-26
- **Final completion:** 2018-12-26
- **Target enrollment:** 68 (ACTUAL)
- **Last updated:** 2021-09-22

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01869725

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01869725, "Comparative Study of Sensitivity of Ga-DOTATOC PET vs Octreoscan SPECT + CT". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT01869725. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*